- Consent Judgment confirms Aobious infringed Promega patents covering luciferase substrate compounds
- Settlement includes permanent injunction against Aobious and monetary payments to Promega
- Promega reaffirms commitment to providing high-quality reagents to scientists through authorized distribution channels
MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation and Aobious Inc. have entered into a settlement agreement to resolve a patent infringement lawsuit related to furimazine and its associated variants. On July 15, 2025, the U.S. District Court for the District of Delaware entered a final Consent Judgment confirming that Aobious infringed four Promega patents, issuing a permanent injunction against Aobious and requiring Aobious to make monetary payments to Promega as agreed upon in the settlement terms.
“Defending our intellectual property supports our mission of providing high-quality, innovative tools to scientists around the world,” says Kevin Kopish, Promega Associate Director of Cell & Protein Analysis. “Acquiring bioluminescence reagents through authorized channels not only ensures that they are optimal quality, but it also supports our continued investment in developing new technologies to advance scientific research.”
Innovation in Bioluminescence
Furimazine is a substrate for NanoLuc® luciferase, a novel enzyme introduced by Promega in 2012. When NanoLuc® luciferase interacts with its substrate, it produces an exceptionally bright luminescent signal. Promega assay platforms such as NanoBiT® and Lumit® technologies enable researchers to use that signal to study proteins in live cells. Several of these technologies have been licensed to authorized partners to further develop solutions to specific customer needs, including CRISPR-edited cell lines.
Promega continues to develop innovative bioluminescence-based research tools based on NanoLuc® luciferase and furimazine. In 2024, the company invested 13.8% of its revenue into research and development, surpassing industry averages.
Learn more about NanoLuc® luciferase and technologies utilizing NanoLuc here.
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com
Contacts
Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com
